AUM $161.1MER 0.50%NAV $55.09Holdings 103Inception Dec 2014
Price Chart
Key Statistics
Previous Close
$55.27Day Range
$54.15$55.27
52-Week Range
$27.24$57.67
Avg Volume
49.9KDividend Yield
2.29%Expense Ratio
0.50%AUM
$161.1MShares Outstanding
2.9METF Grades
?ETF Grades compare this fund against others in the same category using percentile rankings across six factors. Grades range from A+ (top 5%) to F (bottom 20%). Updated daily.Sector Breakdown
| Sector | Weight % |
|---|---|
| Healthcare | 100.00% |
Country Allocation
| Country | Weight % |
|---|---|
| United States | 84.00% |
| Ireland | 3.49% |
| Netherlands | 3.24% |
| Canada | 2.93% |
| Switzerland | 1.74% |
| China | 1.51% |
| Belgium | 1.16% |
| United Kingdom | 1.04% |
| Germany | 0.91% |
Fund Information
- Issuer
- ALPS Funds
- Category
- Healthcare
- Types
- Healthcare
- Inception Date
- Dec 30, 2014
- Exchange
- NYSE_ARCA
- Description
- The ALPS Medical Breakthroughs ETF (SBIO) seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index (PMBI).
Similar ETFs
The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund issued by ALPS Funds that launched on Dec 30, 2014. It currently manages $161.1M in assets under management. The fund charges an expense ratio of 0.50%. The fund holds 103 securities in its portfolio. It falls under the Healthcare category.
Top 10 holdings represent 33.8% of the fund
| Rank | Symbol | Name | Weight % | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | KYMR | Kymera Therapeutics Inc. | 4.20% | 79,460 | $6.9M |
| 2 | MIRM | Mirum Pharmaceuticals Inc. | 3.96% | 58,727 | $6.5M |
| 3 | CELC | Celcuity Inc. | 3.85% | 45,033 | $6.3M |
| 4 | ALKS | Alkermes PLC | 3.50% | 161,789 | $5.7M |
| 5 | CGON | CG oncology Inc. | 3.42% | 82,177 | $5.6M |
| 6 | SYRE | Spyre Therapeutics Inc. | 3.42% | 76,439 | $5.6M |
| 7 | APLS | Apellis Pharmaceuticals Inc. | 3.13% | 124,411 | $5.1M |
| 8 | XENE | Xenon Pharmaceuticals Inc. | 2.90% | 80,963 | $4.7M |
| 9 | APGE | Apogee Therapeutics Inc. | 2.82% | 54,502 | $4.6M |
| 10 | CRNX | Crinetics Pharmaceuticals Inc. | 2.60% | 101,805 | $4.2M |
| 11 | TVTX | Travere Therapeutics Inc. | 2.46% | 89,674 | $4.0M |
| 12 | DNTH | Dianthus Therapeutics Inc. | 2.40% | 43,281 | $3.9M |
| 13 | EWTX | Edgewise Therapeutics Inc. | 2.37% | 104,403 | $3.9M |
| 14 | VKTX | Viking Therapeutics Inc. | 2.22% | 112,462 | $3.6M |
| 15 | ACAD | ACADIA Pharmaceuticals Inc. | 2.18% | 165,932 | $3.6M |
Page 1 of 3
Detailed Returns
| Period | Return | ETF |
|---|---|---|
| 1D | -0.44% | |
| 1W | -0.30% | |
| 1M | -0.10% | |
| 3M | +8.72% | |
| 6M | +21.55% | |
| YTD | +9.70% | |
| 1Y | +94.21% | |
| 3Y | +69.62% | |
| 5Y | +24.97% |
Moving Averages
20-Day MA
$55.26
Below 20-Day MA50-Day MA
$52.74
Above 50-Day MA200-Day MA
$46.01
Above 200-Day MAPrice with Moving Averages
Support & Resistance
52-Week High
$57.67
Current Price
$55.02
52-Week Low
$27.24
$27.24$57.67
Current Yield
2.29%
Annual Dividend
$2.0445
Frequency
1x/year
Last Ex-Date
Dec 19, 2024
Dividend History
| Ex-Date | Amount | Pay Date |
|---|---|---|
| Dec 19, 2024 | $1.1735 | Dec 26, 2024 |
| Dec 21, 2023 | $0.0711 | Dec 27, 2023 |
| Dec 19, 2019 | $0.0158 | Dec 27, 2019 |
| Dec 20, 2018 | $0.7841 | Dec 27, 2018 |
| Dec 21, 2017 | $0.5795 | Dec 28, 2017 |
Dividend Payments Over Time
Category Comparison
| Metric | SBIO | Healthcare(207 ETFs) | Healthcare(24 ETFs) |
|---|---|---|---|
| Fund Info | |||
| Expense Ratio | 0.50% | 0.60% | 0.48% |
| AUM | $161.1M | $1.23B | $629.4M |
| Dividend Yield | 2.29% | 3.25% | 1.61% |
| Avg Volume | 49.9K | 363.2K | 88.0K |
| Holdings | 103 | 177 | 137 |
| Performance | |||
| 1-Month Return | +2.46% | +3.73% | +1.23% |
| 6-Month Return | +24.85% | +8.95% | +6.62% |
| YTD Return | +7.91% | +3.72% | +0.34% |
| 1-Year Return | +97.39% | +29.81% | +22.36% |
Compare with Another ETF
Search for an ETF to compare with SBIO:
FREE DOWNLOAD
The Beginner's Guide to ETFs
20 pages. Zero fluff. Everything you need to start investing in ETFs.
No spam. Unsubscribe anytime.